Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Upadacitinib is an oral selective Janus kinase (JAK)1 inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis and severe atopic dermatitis, including in patients who have not responded well to other therapies. Oral administration in a daily dose.
At the date of the last update we found no published data on its excretion in breast milk.
Its pharmacokinetic data do not allow a good prediction of its possible excretion in breast milk, because although its high volume of distribution would make it difficult, its low molecular weight and fixation to plasma proteins would facilitate it.
Its frequent side effects are respiratory infections, anemia, neutropenia, lymphopenia and elevated liver enzymes.
Pending further published data on this drug in relation to lactation, safer known alternatives are preferable, especially during the neonatal period and in case of prematurity.